Certara, Inc. Form 8-K Summary
Business Context and Reporting Period
Certara, Inc. filed this Current Report on Form 8-K on August 7, 2026, regarding events occurring on August 4, 2026. The filing addresses a clarification issued during the Company's second quarter 2026 earnings conference call and presentation.
Key Financial Metrics
This filing does not report new financial results for the current period but clarifies historical data regarding a divested business unit:
- Divested Business (Regulatory and Medical Writing) 2025 Adjusted EBITDA: Approximately $17 million (including unallocated overhead costs).
- Divested Business 2025 Adjusted EBITDA (Excluding Overhead): Approximately $23 million (excluding unallocated corporate expense remaining with the Company).
The filing text does not provide current period revenue, profit, cash flow, debt, or liquidity figures.
Material Changes and Clarifications
The Company corrected a misstatement made during the Q2 2026 earnings call and in the original earnings presentation. The initial statement incorrectly claimed the divested business generated $17 million in adjusted EBITDA excluding unallocated overhead costs. The corrected statement confirms the $17 million figure includes unallocated overhead costs. An updated earnings presentation has been posted to the Company's investor relations website.
Outlook and Management Commentary
Management stated that this clarification has no impact on:
- Previously reported financial results.
- Year-over-year comparisons.
- The Company's 2026 Financial Outlook.
No new risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the updated Q2 2026 earnings presentation on the Certara investor relations website (ir.certara.com).
- Confirm that the $17 million adjusted EBITDA figure for the divested business includes unallocated overhead costs.
- Review the distinction between the $17 million (with overhead) and $23 million (without overhead) figures for the divested unit's 2025 performance.